Oxycodone News and Research

RSS

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Labopharm, Paladin Labs expand commercial relationship

Labopharm Inc. and Paladin Labs Inc. today announced they have expanded their commercial relationship through three licensing and distribution agreements under which Paladin will distribute two of Labopharm's products in certain jurisdictions.

14 Oct 2010

QRxPharma's A$14 million Placement oversubscribed

QRxPharma Limited has today announced a Placement which raised A$14 million and which was significantly oversubscribed.

1 Oct 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Opiate usage increases in workplace and ER

More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index™ (DTI) released today by Quest Diagnostics Incorporated, the nation's leading provider of diagnostic testing, information and services. Results from more than 5.5 million urine drug tests reveal an 18 percent jump in opiate positives in the general U.S. workforce in a single year (2008 to 2009), and a more than 40 percent climb from 2005 to 2009.

17 Sep 2010

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

Elite Pharmaceuticals, Inc. announced today the signing of a license agreement and a manufacturing and supply agreement with Precision Dose, Inc. which has a wholly owned subsidiary, TAGI Pharma, Inc. which will distribute the products covered by the agreement. Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products in the United States, Puerto Rico and Canada.

17 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Obama administration touts federal efforts to combat health care fraud

The Los Angeles Times: Obama administration officials at a meeting in Los Angeles Thursday touted their efforts to crack down on health care fraud, "saying quickly expanding criminal enterprises are costing taxpayers billions of dollars each year. ... Atty. Gen. Eric H. Holder Jr. and Health and Human Services Secretary Kathleen Sebelius said their agencies were jointly targeting fraud in the federal Medicare and Medicaid programs.

27 Aug 2010

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper-resistant DETERx™ formulation platform. US Patent Number 7,771,707 contains claims that cover Collegium's proprietary extended-release formulations, which are designed to resist dose dumping when subjected to a variety of physical methods of tampering.

18 Aug 2010

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Today, Pisgah Labs, Inc. received a Notice of Allowance from the United States Patent and Trademark office for an important new technology patent addressing global stability problems of thyroid hormone drugs.

17 Aug 2010

Elite Pharmaceuticals reports decrease in manufacturing revenue for fiscal first quarter

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and controlled release product formulations, announced results for the fiscal first quarter ended June 30, 2010.

17 Aug 2010

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm Inc. today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated.

12 Aug 2010

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

9 Aug 2010

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.

30 Jul 2010

Covidien third-quarter 2010 net sales increase 2% to $2.56 billion

Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.

29 Jul 2010

QRxPharma reports positive outcome of European Scientific Advice meetings on MoxDuo IR pain therapy

QRxPharmareported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA).

26 Jul 2010

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Investment report on Catalyst Pharmaceutical Partners

MicroStockProfit.com announces an investment report featuring Catalyst Pharmaceutical Partners Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

12 Jul 2010

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010